Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGNW), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biotechnology company focused on precision T cell therapies and AI-enabled drug development, and its news flow reflects this dual emphasis on science and capital-efficient execution. Company announcements highlight progress across its ExacTcell™ platform, the Tevogen Bio therapeutic pipeline, and the Tevogen.AI analytics division, as well as financial and corporate developments disclosed through SEC filings.
Readers of the Tevogen news page can expect updates on clinical and scientific milestones, such as expanded HLA coverage for its investigational T cell therapy TVGN 489, completion of target identification for additional HLA restrictions, and preclinical work in areas including EBV-associated lymphomas, chronic hepatitis B, and HPV-related cancers. The company also reports on recognition from industry and regional publications, intellectual property developments, and the evolution of its AI capabilities, including its PredicTcell™ model.
Tevogen’s news also covers financial and operational disclosures, including commentary around quarterly reports on Form 10-Q, non-GAAP metrics used by management, and statements on capital efficiency and cash burn. In addition, the company issues releases on corporate actions such as at-the-market equity programs and personal contributions by its founder and CEO to support facilities and community initiatives.
For investors and observers, following Tevogen news provides insight into how the company is advancing its precision T cell therapy programs, building out AI-driven target discovery, and managing its capital structure. Regular updates offer context on the company’s progress in infectious diseases, oncology, and neurology, as well as its stated focus on affordability and sustainable innovation.
Tevogen (Nasdaq: TVGN) reaffirmed capital discipline on March 13, 2026: the lead investor intends to maintain current holdings and the company does not expect to use more than 1% of authorized shares over the next 12 months or until cash-flow positive.
The company said only about 20% of shares are in the tradable float after excluding insider holdings, is prioritizing milestone‑linked stock incentives, is evaluating a one‑time special cash dividend contingent on financial milestones, and is assessing acquisitions that could add $50M+ combined annual revenue; Tevogen noted GAAP may not reflect full asset value and cited independent 2022 valuation above $4B.
Tevogen (Nasdaq: TVGN) reported advances in its Tevogen.AI PredicTcell™ beta, citing improved model metrics and expanded proprietary data and infrastructure on March 13, 2026.
The company reports a database of 655 million peptide sequences, training on 1.8 million data points, recall rising to 92%, and precision to 48%.
Tevogen (Nasdaq: TVGN) said it is advancing investigational T-cell therapy TVGN 489 toward a next clinical phase for Long COVID, timed to International Long COVID Awareness Month.
The company cited proof-of-concept data where treated high-risk patients did not develop Long COVID, expanded HLA coverage to ~65% of U.S. population, a new leadership team effective March 9, 2026, and continued evaluation of acquiring Sciometrix and its Clinicus platform to support real-world monitoring.
Tevogen (Nasdaq: TVGN) named interim leaders across five core verticals to execute an initial diversified growth strategy and announced potential acquisitions expected to operate as subsidiaries.
The company said the targeted transactions could collectively generate annual revenues exceeding $50 million and are expected to close by Q2 2026, subject to customary due diligence and definitive agreements.
Tevogen (Nasdaq: TVGN) CEO Dr. Ryan Saadi provided a shareholder letter (March 6, 2026) outlining strategic acquisition evaluations to complement its immunotherapy and AI platforms. The company said potential targets, if acquired as subsidiaries, may generate aggregate annual revenues in excess of $50 million, subject to due diligence and definitive agreements.
Tevogen emphasized disciplined capital allocation, operational efficiency, and a focus on building a sustainable, revenue-generating healthcare enterprise while pursuing these strategic initiatives.
Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent dated March 5, 2026 to evaluate a potential acquisition of Apozeal Pharmaceutical. The deal could provide Tevogen Generics with an established platform including 11 FDA-approved ANDA products, multiple ANDAs pending, and additional generics in development.
The transaction is subject to due diligence, negotiation of definitive agreements, regulatory approvals, and customary closing conditions, and there is no assurance the acquisition will be completed.
Tevogen (Nasdaq: TVGN) announced a 50-for-1 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid requirement. The split is expected to be effective at 12:01 a.m. on March 6, 2026, with shares trading on a split-adjusted basis under the same symbol and a new CUSIP.
No fractional shares will be issued; holders entitled to fractions will receive cash in lieu. Equity awards, warrants, incentive plan shares and preferred conversions will be proportionally adjusted. The company said the split will not affect underlying operations or total stockholders' equity.
Tevogen (Nasdaq: TVGN) announced a signed, non-exclusive, non-binding Letter of Intent dated Feb 27, 2026 to evaluate a potential acquisition of a global Contract Research Organization (CRO).
If completed, the transaction could expand clinical development capabilities, add revenue-generating services, and support a more capital-efficient growth model while remaining subject to due diligence and definitive agreements.
Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent on Feb 26, 2026 to evaluate a potential transaction to acquire a majority voting interest in Sciometrix and its Clinicus digital care management platform.
The deal would aim to make Tevogen a revenue-generating healthcare enterprise by integrating Clinicus' remote patient monitoring and predictive analytics with Tevogen.AI to support commercialization, value-based care, and optimized clinical trials; the transaction is subject to due diligence, definitive documentation, approvals and customary closing conditions.
Tevogen (Nasdaq: TVGN) signed a non-exclusive, non-binding Letter of Intent on Feb. 26, 2026 to evaluate a potential transaction to acquire a majority voting interest in Sciometrix and its Clinicus digital care management platform.
The deal, if completed, would aim to make Tevogen a revenue-generating healthcare enterprise by integrating Clinicus and remote patient monitoring with Tevogen.AI to accelerate commercialization readiness and enhance data, analytics, and value-based care capabilities. The proposal remains subject to due diligence, definitive agreements, approvals, and customary closing conditions.